Search

Your search keyword '"Baljevic M"' showing total 47 results

Search Constraints

Start Over You searched for: Author "Baljevic M" Remove constraint Author: "Baljevic M"
47 results on '"Baljevic M"'

Search Results

2. PS1414 A PHASE 1B/2 STUDY OF SELINEXOR, CARFILZOMIB, AND DEXAMETHASONE (SKD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

3. PF587 SELINEXOR, POMALIDOMIDE, AND DEXAMETHASONE (SPD) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

4. S1606 SAFETY AND EFFICACY OF COMBINATION OF SELINEXOR, DARATUMUMAB, AND DEXAMETHASONE (SDD) IN PATIENTS WITH MULTIPLE MYELOMA (MM) PREVIOUSLY EXPOSED TO PROTEASOME INHIBITORS AND IMMUNOMODULATORY DRUGS

9. Clonal hematopoiesis and inflammation in the vasculature: CHIVE, a prospective, longitudinal clonal hematopoiesis cohort and biorepository.

10. Efficacy and safety of once weekly selinexor 40 mg versus 60 mg with pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.

12. Novel Heterozygous Missense Variants in Diacylglycerol Kinase Epsilon and Complement Factor I: Potential Pathogenic Association With Atypical Hemolytic Uremic Syndrome.

13. Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.

14. Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma.

15. Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.

17. Impacting T-cell fitness in multiple myeloma: potential roles for selinexor and XPO1 inhibitors.

18. Selinexor-Based Triplet Regimens in Patients With Multiple Myeloma Previously Treated With Anti-CD38 Monoclonal Antibodies.

19. Development and implementation of "handshake rounds": An antibiotic stewardship intervention for hospitalized adult patients with hematologic malignancies.

20. Systemic Light Chain Amyloidosis, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.

21. Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study.

22. Selinexor-based regimens in patients with multiple myeloma after prior anti-B-cell maturation antigen treatment.

24. Cerebral Venous Sinus Thrombosis due to Thrombosis with Thrombocytopenia Syndrome Following Ad26.COV2.S: A First Real-World Case Report of a Male Subject.

25. Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients.

26. NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022.

27. Optimizing Thromboembolism Prophylaxis for the Contemporary Age of Multiple Myeloma.

28. Bortezomib-Induced Perimyocarditis in a Multiple Myeloma Patient: A Case Report.

29. Bortezomib-Induced Reversible Cardiomyopathy: Recovered With Guideline-Directed Medical Therapy.

30. Evolving Role of Autologous Stem Cell Transplantation for Light Chain Amyloidosis in the Modern Era.

31. The evaluation and management of monoclonal gammopathy of renal significance and monoclonal gammopathy of neurological significance.

32. Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology.

33. Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma.

34. Intravenous Immunoglobulin G Suppresses Heat Shock Protein (HSP)-70 Expression and Enhances the Activity of HSP90 and Proteasome Inhibitors.

35. NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020.

36. Pharmacodynamics and pharmacokinetics of proteasome inhibitors for the treatment of multiple myeloma.

37. Present and Future of Immunotherapy in the Management of Multiple Myeloma.

38. Serendipitous Discovery of Factor VII Deficiency and the Ensuing Dilemma.

39. Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma.

40. Telomere Length Recovery: A Strong Predictor of Overall Survival in Acute Promyelocytic Leukemia.

41. Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia.

42. Epstein-barr virus-related hemophagocytic lymphohistiocytosis: hematologic emergency in the critical care setting.

43. Translocation t(11;17) in de novo myelodysplastic syndrome not associated with acute myeloid or acute promyelocytic leukemia.

44. Curing all patients with acute promyelocytic leukemia: are we there yet?

45. Slitrk5 deficiency impairs corticostriatal circuitry and leads to obsessive-compulsive-like behaviors in mice.

46. Angiomodulin is a specific marker of vasculature and regulates vascular endothelial growth factor-A-dependent neoangiogenesis.

47. CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors.

Catalog

Books, media, physical & digital resources